Circulating miR-148a associates with sensitivity to adiponectin levels in human metabolic surgery for weight loss.
We sought to discover secreted biomarkers to monitor the recovery of physiological adiponectin levels with metabolic surgery, focusing on epigenetic changes that might predict adiponectin function. We conducted a prospective observational study of patients undergoing metabolic surgery by Roux-en-Y gastric bypass (RYGB) for weight loss in a single center (IRB GHS # 1207-27). All patients (n=33; 27 females; 6 males) signed informed consent. Metabolites, adiponectin, and miR-148a were measured in fasting plasma. We followed MIQE for transcript profiles. Patients lost on average 47±12% excess BMI (%EBMI) after 12 weeks. Adiponectin pre, post or delta [post minus pre] did not correlate with %EBMIL. A decrease in adiponectin following weight loss surgery was observed in a subset of patients, chi-square test of independence rejects the null hypotheses that the liver DNMT1 and delta adiponectin are independent (Chi-square statistics χ2 38 = 6.9205, P= 0.00852, n=33), as well as miR-148a and delta adiponectin are independent (Chisquare statistics χ2 40 = 9.6823, P= 0.00186, n=33). The presence of plasma miR-148a allows identification of patients that appear to be adiponectin insensitive at baseline. We combined the presence of plasma miR-148a, the concentration of total adiponectin and the expression of DNA methyltransferase 1 (DNMT1) in liver biopsy tissue to identify patients with non-physiological adiponectin. Weight loss and physical activity interventions complemented with the new method presented here could serve to monitor the physiological levels of adiponectin, thought to be important for long-term weight loss maintenance.